Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.
Identifieur interne : 000245 ( Main/Exploration ); précédent : 000244; suivant : 000246Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.
Auteurs : A D Thompson [Australie] ; H J Jones [Royaume-Uni] ; J. Heron [Royaume-Uni] ; J. Hibbeln [États-Unis] ; S. Sullivan [Royaume-Uni] ; S. Zammit [Royaume-Uni]Source :
- Schizophrenia research [ 1573-2509 ] ; 2020.
Abstract
BACKGROUND
Long chain polyunsaturated fatty acid (PUFA) levels have been implicated in the pathology of psychotic disorders. We investigated the relationship between childhood PUFA levels and later psychotic experiences (PE's) in a large birth cohort.
METHODS
Plasma levels of Ω-3 and Ω-6 fatty acids (FA's) were assayed at ages 7 and 16 years. PE's were assessed at ages 12 and 18 years using a semi-structured interview. Primary outcome was any PE's at 18 years; sensitivity analyses examined incident PE's between ages 12 and 18 years, persistent PE's (at 12 and 18) and psychotic disorder at 18 years. Genetic instruments for Ω-3 and Ω-6 were derived and used in a multivariable Mendelian Randomization analysis.
RESULTS
Higher levels of Ω-6 FA's AA, OA and AdA at age 7 years were weakly associated with a reduced risk for PE's at 18 years, however, effect sizes were small and attenuated after adjusting for confounders (strongest evidence for OA; adjusted OR, 0.842; 95% CI, 0.711, 0.998; p, 0.048). Total Ω-6 levels at age 16 years were associated with an increased odds of psychotic disorder at age 18 years. However, there was no association between Ω-6/Ω-3 ratio and psychosis outcomes, nor with genetic instruments of total Ω-3 or Ω-6 levels.
CONCLUSIONS
There is no strong evidence that total plasma Ω-3 FA levels or Ω-6/Ω-3 ratios in childhood and mid-adolescence are associated with increased risk for PE's or psychotic disorder, but very marginal evidence that alterations in the Ω-6 pathway at developmental time points might influence risk
DOI: 10.1016/j.schres.2020.09.018
PubMed: 33067055
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.</title><author><name sortKey="Thompson, A D" sort="Thompson, A D" uniqKey="Thompson A" first="A D" last="Thompson">A D Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Division of Mental Health and Wellbeing, University of Warwick, UK; Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3250, Australia. Electronic address: Andrew.thompson@orygen.org.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Mental Health and Wellbeing, University of Warwick, UK; Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3250</wicri:regionArea><wicri:noRegion>VIC 3250</wicri:noRegion></affiliation></author><author><name sortKey="Jones, H J" sort="Jones, H J" uniqKey="Jones H" first="H J" last="Jones">H J Jones</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol</wicri:regionArea><wicri:noRegion>University of Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Heron, J" sort="Heron, J" uniqKey="Heron J" first="J" last="Heron">J. Heron</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol</wicri:regionArea><wicri:noRegion>Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Hibbeln, J" sort="Hibbeln, J" uniqKey="Hibbeln J" first="J" last="Hibbeln">J. Hibbeln</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Membrane Biochemistry and Biophysics, Section of Nutritional Neuroscience, National Institute for Health, Bethesda, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Membrane Biochemistry and Biophysics, Section of Nutritional Neuroscience, National Institute for Health, Bethesda</wicri:regionArea><wicri:noRegion>Bethesda</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, S" sort="Sullivan, S" uniqKey="Sullivan S" first="S" last="Sullivan">S. Sullivan</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR CLAHRC West, Whitefriars, Lewins Mead, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR CLAHRC West, Whitefriars, Lewins Mead, Bristol</wicri:regionArea><wicri:noRegion>Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Zammit, S" sort="Zammit, S" uniqKey="Zammit S" first="S" last="Zammit">S. Zammit</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK; MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK; MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff</wicri:regionArea><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33067055</idno><idno type="pmid">33067055</idno><idno type="doi">10.1016/j.schres.2020.09.018</idno><idno type="wicri:Area/Main/Corpus">000056</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000056</idno><idno type="wicri:Area/Main/Curation">000056</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000056</idno><idno type="wicri:Area/Main/Exploration">000056</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.</title><author><name sortKey="Thompson, A D" sort="Thompson, A D" uniqKey="Thompson A" first="A D" last="Thompson">A D Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Division of Mental Health and Wellbeing, University of Warwick, UK; Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3250, Australia. Electronic address: Andrew.thompson@orygen.org.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Mental Health and Wellbeing, University of Warwick, UK; Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3250</wicri:regionArea><wicri:noRegion>VIC 3250</wicri:noRegion></affiliation></author><author><name sortKey="Jones, H J" sort="Jones, H J" uniqKey="Jones H" first="H J" last="Jones">H J Jones</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol</wicri:regionArea><wicri:noRegion>University of Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Heron, J" sort="Heron, J" uniqKey="Heron J" first="J" last="Heron">J. Heron</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol</wicri:regionArea><wicri:noRegion>Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Hibbeln, J" sort="Hibbeln, J" uniqKey="Hibbeln J" first="J" last="Hibbeln">J. Hibbeln</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Membrane Biochemistry and Biophysics, Section of Nutritional Neuroscience, National Institute for Health, Bethesda, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Membrane Biochemistry and Biophysics, Section of Nutritional Neuroscience, National Institute for Health, Bethesda</wicri:regionArea><wicri:noRegion>Bethesda</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, S" sort="Sullivan, S" uniqKey="Sullivan S" first="S" last="Sullivan">S. Sullivan</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR CLAHRC West, Whitefriars, Lewins Mead, Bristol, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR CLAHRC West, Whitefriars, Lewins Mead, Bristol</wicri:regionArea><wicri:noRegion>Bristol</wicri:noRegion></affiliation></author><author><name sortKey="Zammit, S" sort="Zammit, S" uniqKey="Zammit S" first="S" last="Zammit">S. Zammit</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK; MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK; MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff</wicri:regionArea><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author></analytic><series><title level="j">Schizophrenia research</title><idno type="eISSN">1573-2509</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Long chain polyunsaturated fatty acid (PUFA) levels have been implicated in the pathology of psychotic disorders. We investigated the relationship between childhood PUFA levels and later psychotic experiences (PE's) in a large birth cohort.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Plasma levels of Ω-3 and Ω-6 fatty acids (FA's) were assayed at ages 7 and 16 years. PE's were assessed at ages 12 and 18 years using a semi-structured interview. Primary outcome was any PE's at 18 years; sensitivity analyses examined incident PE's between ages 12 and 18 years, persistent PE's (at 12 and 18) and psychotic disorder at 18 years. Genetic instruments for Ω-3 and Ω-6 were derived and used in a multivariable Mendelian Randomization analysis.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Higher levels of Ω-6 FA's AA, OA and AdA at age 7 years were weakly associated with a reduced risk for PE's at 18 years, however, effect sizes were small and attenuated after adjusting for confounders (strongest evidence for OA; adjusted OR, 0.842; 95% CI, 0.711, 0.998; p, 0.048). Total Ω-6 levels at age 16 years were associated with an increased odds of psychotic disorder at age 18 years. However, there was no association between Ω-6/Ω-3 ratio and psychosis outcomes, nor with genetic instruments of total Ω-3 or Ω-6 levels.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>There is no strong evidence that total plasma Ω-3 FA levels or Ω-6/Ω-3 ratios in childhood and mid-adolescence are associated with increased risk for PE's or psychotic disorder, but very marginal evidence that alterations in the Ω-6 pathway at developmental time points might influence risk</p></div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33067055</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2509</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0920-9964(20)30476-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2020.09.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long chain polyunsaturated fatty acid (PUFA) levels have been implicated in the pathology of psychotic disorders. We investigated the relationship between childhood PUFA levels and later psychotic experiences (PE's) in a large birth cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma levels of Ω-3 and Ω-6 fatty acids (FA's) were assayed at ages 7 and 16 years. PE's were assessed at ages 12 and 18 years using a semi-structured interview. Primary outcome was any PE's at 18 years; sensitivity analyses examined incident PE's between ages 12 and 18 years, persistent PE's (at 12 and 18) and psychotic disorder at 18 years. Genetic instruments for Ω-3 and Ω-6 were derived and used in a multivariable Mendelian Randomization analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Higher levels of Ω-6 FA's AA, OA and AdA at age 7 years were weakly associated with a reduced risk for PE's at 18 years, however, effect sizes were small and attenuated after adjusting for confounders (strongest evidence for OA; adjusted OR, 0.842; 95% CI, 0.711, 0.998; p, 0.048). Total Ω-6 levels at age 16 years were associated with an increased odds of psychotic disorder at age 18 years. However, there was no association between Ω-6/Ω-3 ratio and psychosis outcomes, nor with genetic instruments of total Ω-3 or Ω-6 levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is no strong evidence that total plasma Ω-3 FA levels or Ω-6/Ω-3 ratios in childhood and mid-adolescence are associated with increased risk for PE's or psychotic disorder, but very marginal evidence that alterations in the Ω-6 pathway at developmental time points might influence risk<sup>2</sup>.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Division of Mental Health and Wellbeing, University of Warwick, UK; Orygen, the Centre of Excellence in Youth Mental Health, 35 Poplar Rd, Parkville, VIC 3250, Australia. Electronic address: Andrew.thompson@orygen.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>H J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heron</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hibbeln</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Membrane Biochemistry and Biophysics, Section of Nutritional Neuroscience, National Institute for Health, Bethesda, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR CLAHRC West, Whitefriars, Lewins Mead, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zammit</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust, University of Bristol, UK; MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Birth cohort</Keyword><Keyword MajorTopicYN="N">Long chain polyunsaturated fatty acid</Keyword><Keyword MajorTopicYN="N">Psychosis</Keyword><Keyword MajorTopicYN="N">Psychotic experiences</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33067055</ArticleId><ArticleId IdType="pii">S0920-9964(20)30476-X</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2020.09.018</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Royaume-Uni</li><li>États-Unis</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Thompson, A D" sort="Thompson, A D" uniqKey="Thompson A" first="A D" last="Thompson">A D Thompson</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Jones, H J" sort="Jones, H J" uniqKey="Jones H" first="H J" last="Jones">H J Jones</name></noRegion><name sortKey="Heron, J" sort="Heron, J" uniqKey="Heron J" first="J" last="Heron">J. Heron</name><name sortKey="Sullivan, S" sort="Sullivan, S" uniqKey="Sullivan S" first="S" last="Sullivan">S. Sullivan</name><name sortKey="Zammit, S" sort="Zammit, S" uniqKey="Zammit S" first="S" last="Zammit">S. Zammit</name></country><country name="États-Unis"><noRegion><name sortKey="Hibbeln, J" sort="Hibbeln, J" uniqKey="Hibbeln J" first="J" last="Hibbeln">J. Hibbeln</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000245 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000245 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33067055
|texte= Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33067055" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |